336 related articles for article (PubMed ID: 12800807)
21. Efficient strategy for obtaining reliable pharmacokinetic parameters in population compartmental approaches.
Lee J; Kang D; Kim E; Kim BH
Int J Clin Pharmacol Ther; 2016 Jan; 54(1):11-8. PubMed ID: 26521928
[TBL] [Abstract][Full Text] [Related]
22. Estimating inestimable standard errors in population pharmacokinetic studies: the bootstrap with Winsorization.
Ette EI; Onyiah LC
Eur J Drug Metab Pharmacokinet; 2002; 27(3):213-24. PubMed ID: 12365204
[TBL] [Abstract][Full Text] [Related]
23. [Modeling and simulation activities to design sampling scheme for population pharmacokinetic study on amlodipine].
Zuo XC; Yuan H; Zhang BK; Ng CM; Barrett JS; Yang GP; Huang ZJ; Pei Q; Guo R; Zhou YN; Jing NN; Di W
Yao Xue Xue Bao; 2012 Jul; 47(7):941-6. PubMed ID: 22993862
[TBL] [Abstract][Full Text] [Related]
24. Comparison of ED, EID, and API criteria for the robust optimization of sampling times in pharmacokinetics.
Tod M; Rocchisani JM
J Pharmacokinet Biopharm; 1997 Aug; 25(4):515-37. PubMed ID: 9561492
[TBL] [Abstract][Full Text] [Related]
25. The influence of assay variability on pharmacokinetic parameter estimation.
Graves DA; Locke CS; Muir KT; Miller RP
J Pharmacokinet Biopharm; 1989 Oct; 17(5):571-92. PubMed ID: 2614686
[TBL] [Abstract][Full Text] [Related]
26. Circadian rhythm of 5-fluorouracil population pharmacokinetics in patients with metastatic colorectal cancer.
Bressolle F; Joulia JM; Pinguet F; Ychou M; Astre C; Duffour J; Gomeni R
Cancer Chemother Pharmacol; 1999; 44(4):295-302. PubMed ID: 10447576
[TBL] [Abstract][Full Text] [Related]
27. Impact of dose selection on parameter estimation using a rapid binding approximation model of target-mediated drug disposition.
Marathe A; Van Wart S; Mager DE
J Pharmacokinet Pharmacodyn; 2011 Apr; 38(2):223-35. PubMed ID: 21165681
[TBL] [Abstract][Full Text] [Related]
28. Estimation of pharmacokinetic parameters by orthogonal regression: comparison of four algorithms.
Tod M; Aouimer A; Petitjean O
Comput Methods Programs Biomed; 2002 Jan; 67(1):13-26. PubMed ID: 11750944
[TBL] [Abstract][Full Text] [Related]
29. [Effects of multiple-trough sampling design and algorithm on the estimation of population and individual pharmacokinetic parameters].
Ling J; Qian LX; Ding JJ; Jiao Z
Yao Xue Xue Bao; 2014 May; 49(5):686-94. PubMed ID: 25151742
[TBL] [Abstract][Full Text] [Related]
30. Desipramine, substrate for CYP2D6 activity: population pharmacokinetic model and design elements of drug-drug interaction trials.
Gueorguieva I; Jackson K; Wrighton SA; Sinha VP; Chien JY
Br J Clin Pharmacol; 2010 Oct; 70(4):523-36. PubMed ID: 20840444
[TBL] [Abstract][Full Text] [Related]
31. Population pharmacokinetics of tacrolimus in whole blood and plasma in asian liver transplant patients.
Sam WJ; Tham LS; Holmes MJ; Aw M; Quak SH; Lee KH; Lim SG; Prabhakaran K; Chan SY; Ho PC
Clin Pharmacokinet; 2006; 45(1):59-75. PubMed ID: 16430311
[TBL] [Abstract][Full Text] [Related]
32. Patient characteristics influencing ciclosporin pharmacokinetics and accurate Bayesian estimation of ciclosporin exposure in heart, lung and kidney transplant patients.
Saint-Marcoux F; Marquet P; Jacqz-Aigrain E; Bernard N; Thiry P; Le Meur Y; Rousseau A
Clin Pharmacokinet; 2006; 45(9):905-22. PubMed ID: 16928152
[TBL] [Abstract][Full Text] [Related]
33. Easy and reliable maximum a posteriori Bayesian estimation of pharmacokinetic parameters with the open-source R package mapbayr.
Le Louedec F; Puisset F; Thomas F; Chatelut É; White-Koning M
CPT Pharmacometrics Syst Pharmacol; 2021 Oct; 10(10):1208-1220. PubMed ID: 34342170
[TBL] [Abstract][Full Text] [Related]
34. A Bayesian approach for the estimation of patient compliance based on the last sampling information.
Barrière O; Li J; Nekka F
J Pharmacokinet Pharmacodyn; 2011 Jun; 38(3):333-51. PubMed ID: 21445612
[TBL] [Abstract][Full Text] [Related]
35. Assessing convergence of Markov chain Monte Carlo simulations in hierarchical Bayesian models for population pharmacokinetics.
Dodds MG; Vicini P
Ann Biomed Eng; 2004 Sep; 32(9):1300-13. PubMed ID: 15493516
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of Bayesian estimation of pharmacokinetic parameters.
Tsuchiwata S; Mihara K; Yafune A; Ogata H
Ther Drug Monit; 2005 Feb; 27(1):18-24. PubMed ID: 15665741
[TBL] [Abstract][Full Text] [Related]
37. Diazepam pharamacokinetics from preclinical to phase I using a Bayesian population physiologically based pharmacokinetic model with informative prior distributions in WinBUGS.
Gueorguieva I; Aarons L; Rowland M
J Pharmacokinet Pharmacodyn; 2006 Oct; 33(5):571-94. PubMed ID: 16810558
[TBL] [Abstract][Full Text] [Related]
38. Considerations in analyzing single-trough concentrations using mixed-effects modeling.
Booth BP; Gobburu JV
J Clin Pharmacol; 2003 Dec; 43(12):1307-15. PubMed ID: 14615466
[TBL] [Abstract][Full Text] [Related]
39. A limited sampling strategy for estimating individual pharmacokinetic parameters of coagulation factor VIII in patients with hemophilia A.
Bolon-Larger M; Chamouard V; Bressolle F; Boulieu R
Ther Drug Monit; 2007 Feb; 29(1):20-6. PubMed ID: 17304146
[TBL] [Abstract][Full Text] [Related]
40. Sirolimus population pharmacokinetic/pharmacogenetic analysis and bayesian modelling in kidney transplant recipients.
Djebli N; Rousseau A; Hoizey G; Rerolle JP; Toupance O; Le Meur Y; Marquet P
Clin Pharmacokinet; 2006; 45(11):1135-48. PubMed ID: 17048977
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
